Core Business and Technology

Maxygen is a fee-for-service contract research provider that offers custom and collaborative programs to serve the protein engineering and optimization needs of the biotechnology industry. It operates as a specialist in the field of directed evolution. This laboratory-based process mimics the powerful natural process of evolution, enabling scientists to accelerate the development of proteins and genes with desired characteristics, such as enhanced stability, activity, or specificity, for use in therapeutics, industrial enzymes, or agriculture.

The central proprietary technology is Molecular Breeding, which is also referred to as DNA shuffling.

• Technology Mechanism: The platform uses recombination-based technologies to create extensive genetic diversity. Parent input genes, often sourced from phylogenetic homologs (proteins with similar sequences from different species), are fragmented and then reassembled in vitro through homologous recombination. This process generates recombinant DNA libraries that contain millions of potential chimeric variants. By shuffling and recombining the genetic material from different parental genes, Maxygen can rapidly explore a vast landscape of possible protein variants.
• Directed Evolution Application: Following the creation of these massive libraries of genetic variants, the company applies specific environmental selective pressures in a laboratory setting. This allows for high-throughput screening to identify and select the variants that exhibit the desired, improved functional traits for a particular application. This effectively guides the "evolution" of the protein toward an optimal form.

Products and Services Offered

As a CRO, Maxygen's current business model is centered on providing specialized, custom directed evolution services to clients across all sectors of the biotech industry, including synthetic biology, metabolic engineering, gene therapy, immunotherapy, and gene editing.

Key Service Offerings

1. Custom Protein Engineering Programs: Maxygen provides full discovery programs, collaborating with partners from initial project conception to the identification of optimal protein variants. The company???s expertise includes:

   • Strategic Project Development: Determining the best project strategy, defining goals, milestones, and deliverables.
   • Library Design Strategies: Employing advanced techniques, including EvoGenerative??? computational methods, for scalable library design and to maximize the functional content of the recombinant libraries.
   • Assay Development: Assisting in the creation or refinement of assays necessary to screen for the desired functional trait in the laboratory.

2. Molecular Biology Services: Beyond the core directed evolution programs, Maxygen offers foundational molecular biology support on a fee-for-service basis. These services include:

   • DNA Synthesis and Assembly: Utilizing proprietary technologies for the creation and assembly of DNA molecules.
   • Mutational and Cloning Technologies: Enabling various complex molecular biology workflows for partners.
   • Combinatorial Library Provision: The ability to provide combinatorial libraries directly to clients for their own in-house screening.

Business Model and Value Proposition

Maxygen operates solely on a fee-for-service basis, meaning it performs the contracted research and development work for its partners. A critical component of its value proposition is the principle of Retained Ownership: clients retain full rights and ownership to the final variants, materials, and results identified through the collaborative programs. This model is designed to assist clients in solving their protein engineering bottlenecks and accelerating their product development timelines.

Historical Context and Legacy

The original Maxygen Inc., founded in 1997 in Redwood City, California, was focused on using the Molecular Breeding technology for internal product development, primarily in the biopharmaceutical space.

• Biopharmaceutical Development: The original Maxygen Inc. had its own clinical pipeline. This included a novel G-CSF (Granulocyte-Colony Stimulating Factor) for the treatment of chemotherapy-induced neutropenia, which entered clinical trials in 2006. It also pursued a preclinical program, MAXY-4, a novel CTLA4-Ig therapeutic intended for the treatment of rheumatoid arthritis and other autoimmune diseases.
• Spinoffs and Licensing: To commercialize the broad potential of the Molecular Breeding platform, Maxygen spun off or exclusively licensed the technology to subsidiaries or partners focused on specific market segments. Notable examples include:
  • Codexis: Established to focus on enzyme and chemical applications.
  • MaxyAg: Established to focus on agricultural applications.
• Dissolution and Re-establishment: The original Maxygen Inc. dissolved in 2013. However, a group of scientists, investors, and specialists re-established the company as Maxygen LLC in 2017 to offer the well-established Molecular Breeding technology directly to the entire biotech industry as a third-party service provider.